DELFI Diagnostics Appoints Charles Newton to Board of Directors [Yahoo! Finance]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Yahoo! Finance
PALO ALTO, Calif. April 27, 2026 /PRNewswire/ - DELFI Diagnostics, Inc. developer of innovative AI-powered blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced the appointment of Charles "Charlie" Newton to its Board of Directors. Mr. Newton brings nearly three decades of healthcare finance and executive leadership experience to DELFI as the company reads out pivotal data that advances its lead product, FirstLook™ Lung, toward FDA submission and positions it for broad commercial adoption. DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible, and deliver a new way to help detect cancer. (PRNewsfoto/DELFI Diagnostics) "Charlie's deep financial expertise combined with his experience with emerging companies gives him a unique and valuable perspective. We are thrilled he has chosen to join us in our mission to deliver a paradigm-changing screening test for lung cancer," said
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma (LYEL) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LYEL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell"MarketBeat
- Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- A First Look At Lyell Immunopharma [Seeking Alpha]Seeking Alpha
- Lyell Immunopharma (LYEL) is now covered by Needham & Company LLC. They set a "buy" rating and a $44.00 price target on the stock.MarketBeat
- Lyell Immunopharma (LYEL) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
LYEL
Sec Filings
- 4/24/26 - Form ARS
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form DEF
- LYEL's page on the SEC website